Angiopoietin 1 Receptor - Pipeline Review, H2 2019
Angiopoietin 1 Receptor - Pipeline Review, H2 2019
SUMMARY
According to the recently published report 'Angiopoietin 1 Receptor - Pipeline Review, H2 2019'; Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) pipeline Target constitutes close to 19 molecules. Out of which approximately 16 molecules are developed by companies and remaining by the universities/institutes.
Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) - Angiopoietin-1 receptor or CD202B is a protein encoded by the TEK gene.It regulates angiogenesis, endothelial cell survival, proliferation, migration, adhesion and cell spreading, reorganization of the actin cytoskeleton. It also maintains of vascular quiescence. It has anti-inflammatory effects by preventing the leakage of proinflammatory plasma proteins and leukocytes from blood vessels. It is required for normal angiogenesis and heart development during embryogenesis. It is required for post-natal hematopoiesis.
The report 'Angiopoietin 1 Receptor - Pipeline Review, H2 2019' outlays comprehensive information on the Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 3, 1, 7, 1 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 2 molecules, respectively.
Report covers products from therapy areas Oncology, Ophthalmology, Metabolic Disorders, Cardiovascular, Dermatology, Genito Urinary System And Sex Hormones, Male Health, Non Malignant Disorders and Respiratory which include indications Gastric Cancer, Metastatic Colorectal Cancer, Adenocarcinoma Of The Gastroesophageal Junction, Breast Cancer, Endometrial Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Adenocarcinoma, Bile Duct Cancer (Cholangiocarcinoma), Bladder Cancer, Colorectal Cancer, Esophageal Cancer, Ewing Sarcoma, Gastrointestinal Stromal Tumor (GIST), Glioblastoma Multiforme (GBM), Hepatocellular Carcinoma, Melanoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Biliary Tract Cancer, Metastatic Breast Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Melanoma, Metastatic Ovarian Cancer, Metastatic Uveal Melanoma, Open-Angle Glaucoma, Osteosarcoma, Renal Cell Carcinoma, Rhabdomyosarcoma, Soft Tissue Sarcoma, Solid Tumor, Thyroid Cancer, Transitional Cell Cancer (Urothelial Cell Cancer), Acute Lung Injury, Acute Renal Failure (ARF) (Acute Kidney Injury), Acute Respiratory Distress Syndrome, Adenoid Cystic Carcinoma (ACC), Adrenocortical Carcinoma (Adrenal Cortex Cancer), Asthma, Atopic Dermatitis (Atopic Eczema), Carcinoid Tumor, Choroidal Neovascularization, Diabetic Foot Ulcers, Diabetic Ischemic Foot Ulcers, Diabetic Macular Edema, Diabetic Neuropathic Foot Ulcers, Epithelial Ovarian Cancer, Erectile Dysfunction, Fallopian Tube Cancer, Follicular Thyroid Cancer, Gallbladder Cancer, Gastroesophageal (GE) Junction Carcinomas, Glaucoma, Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, High-Grade Glioma, Leiomyosarcoma, Liposarcoma, Liver Cancer, Lung Cancer, Macular Edema, Malignant Pleural Mesothelioma, Mantle Cell Lymphoma, Medullary Thyroid Cancer, Merkel Cell Carcinoma, Metastatic Prostate Cancer, Metastatic Renal Cell Carcinoma, Myelodysplastic Syndrome, Myelofibrosis, Myocardial Infarction, Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET), Non-Hodgkin Lymphoma, Non-Rhabdomyosarcoma, Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Osteolytic Bone Metastasis, Ovarian Cancer, Pancreatic Cancer, Papillary Renal Cell Carcinoma, Papillary Thyroid Cancer, Paraganglioma (Glomus Jugulare Tumor), Penile Cancer, Peritoneal Cancer, Pheochromocytoma, Plexiform Neurofibroma, Prostate Cancer, Recurrent Glioblastoma Multiforme (GBM), Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Refractory Multiple Myeloma, Relapsed Multiple
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
According to the recently published report 'Angiopoietin 1 Receptor - Pipeline Review, H2 2019'; Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) pipeline Target constitutes close to 19 molecules. Out of which approximately 16 molecules are developed by companies and remaining by the universities/institutes.
Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) - Angiopoietin-1 receptor or CD202B is a protein encoded by the TEK gene.It regulates angiogenesis, endothelial cell survival, proliferation, migration, adhesion and cell spreading, reorganization of the actin cytoskeleton. It also maintains of vascular quiescence. It has anti-inflammatory effects by preventing the leakage of proinflammatory plasma proteins and leukocytes from blood vessels. It is required for normal angiogenesis and heart development during embryogenesis. It is required for post-natal hematopoiesis.
The report 'Angiopoietin 1 Receptor - Pipeline Review, H2 2019' outlays comprehensive information on the Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 3, 1, 7, 1 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 2 molecules, respectively.
Report covers products from therapy areas Oncology, Ophthalmology, Metabolic Disorders, Cardiovascular, Dermatology, Genito Urinary System And Sex Hormones, Male Health, Non Malignant Disorders and Respiratory which include indications Gastric Cancer, Metastatic Colorectal Cancer, Adenocarcinoma Of The Gastroesophageal Junction, Breast Cancer, Endometrial Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Adenocarcinoma, Bile Duct Cancer (Cholangiocarcinoma), Bladder Cancer, Colorectal Cancer, Esophageal Cancer, Ewing Sarcoma, Gastrointestinal Stromal Tumor (GIST), Glioblastoma Multiforme (GBM), Hepatocellular Carcinoma, Melanoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Biliary Tract Cancer, Metastatic Breast Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Melanoma, Metastatic Ovarian Cancer, Metastatic Uveal Melanoma, Open-Angle Glaucoma, Osteosarcoma, Renal Cell Carcinoma, Rhabdomyosarcoma, Soft Tissue Sarcoma, Solid Tumor, Thyroid Cancer, Transitional Cell Cancer (Urothelial Cell Cancer), Acute Lung Injury, Acute Renal Failure (ARF) (Acute Kidney Injury), Acute Respiratory Distress Syndrome, Adenoid Cystic Carcinoma (ACC), Adrenocortical Carcinoma (Adrenal Cortex Cancer), Asthma, Atopic Dermatitis (Atopic Eczema), Carcinoid Tumor, Choroidal Neovascularization, Diabetic Foot Ulcers, Diabetic Ischemic Foot Ulcers, Diabetic Macular Edema, Diabetic Neuropathic Foot Ulcers, Epithelial Ovarian Cancer, Erectile Dysfunction, Fallopian Tube Cancer, Follicular Thyroid Cancer, Gallbladder Cancer, Gastroesophageal (GE) Junction Carcinomas, Glaucoma, Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, High-Grade Glioma, Leiomyosarcoma, Liposarcoma, Liver Cancer, Lung Cancer, Macular Edema, Malignant Pleural Mesothelioma, Mantle Cell Lymphoma, Medullary Thyroid Cancer, Merkel Cell Carcinoma, Metastatic Prostate Cancer, Metastatic Renal Cell Carcinoma, Myelodysplastic Syndrome, Myelofibrosis, Myocardial Infarction, Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET), Non-Hodgkin Lymphoma, Non-Rhabdomyosarcoma, Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Osteolytic Bone Metastasis, Ovarian Cancer, Pancreatic Cancer, Papillary Renal Cell Carcinoma, Papillary Thyroid Cancer, Paraganglioma (Glomus Jugulare Tumor), Penile Cancer, Peritoneal Cancer, Pheochromocytoma, Plexiform Neurofibroma, Prostate Cancer, Recurrent Glioblastoma Multiforme (GBM), Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Refractory Multiple Myeloma, Relapsed Multiple
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1)
- The report reviews Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) - Overview
Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) - Companies Involved in Therapeutics Development
AsclepiX Therapeutics Inc
Bayer AG
Deciphera Pharmaceuticals Inc
Eddingpharm Inc
Eli Lilly and Co
Exelixis Inc
Pfizer Inc
PharmAbcine Inc
Q BioMed Inc
Samjin Pharm Co Ltd
Teva Pharmaceutical Industries Ltd
Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) - Drug Profiles
ACX-107 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AP-185 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AP-216 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AV-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cabometyx - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cabozantinib s-malate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CEP-11981 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EDP-317 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MAN-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MAN-11 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
merestinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pexmetinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PMC-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rebastinib tosylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
regorafenib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SJP-1601 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit VEGFR2, TIE 2 and EPHB4 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Agonize TIE2 for Glaucoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VDAU-11 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) - Dormant Products
Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) - Discontinued Products
Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) - Product Development Milestones
Featured News & Press Releases
Appendix
Global Markets Direct Report Coverage
Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) - Overview
Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) - Companies Involved in Therapeutics Development
AsclepiX Therapeutics Inc
Bayer AG
Deciphera Pharmaceuticals Inc
Eddingpharm Inc
Eli Lilly and Co
Exelixis Inc
Pfizer Inc
PharmAbcine Inc
Q BioMed Inc
Samjin Pharm Co Ltd
Teva Pharmaceutical Industries Ltd
Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) - Drug Profiles
ACX-107 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AP-185 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AP-216 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AV-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cabometyx - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cabozantinib s-malate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CEP-11981 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EDP-317 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MAN-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MAN-11 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
merestinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pexmetinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PMC-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rebastinib tosylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
regorafenib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SJP-1601 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit VEGFR2, TIE 2 and EPHB4 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Agonize TIE2 for Glaucoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VDAU-11 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) - Dormant Products
Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) - Discontinued Products
Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 2.7.10.1) - Product Development Milestones
Featured News & Press Releases
Appendix
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..3), H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..4), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Products under Development by Companies, H2 2019 (Contd..6), H2 2019
Products under Development by Companies, H2 2019 (Contd..7), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by AsclepiX Therapeutics Inc, H2 2019
Pipeline by Bayer AG, H2 2019
Pipeline by Deciphera Pharmaceuticals Inc, H2 2019
Pipeline by Eddingpharm Inc, H2 2019
Pipeline by Eli Lilly and Co, H2 2019
Pipeline by Exelixis Inc, H2 2019
Pipeline by Pfizer Inc, H2 2019
Pipeline by PharmAbcine Inc, H2 2019
Pipeline by Q BioMed Inc, H2 2019
Pipeline by Samjin Pharm Co Ltd, H2 2019
Pipeline by Teva Pharmaceutical Industries Ltd, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Dormant Products, H2 2019 (Contd..2), H2 2019
Discontinued Products, H2 2019
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..3), H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..4), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Products under Development by Companies, H2 2019 (Contd..6), H2 2019
Products under Development by Companies, H2 2019 (Contd..7), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by AsclepiX Therapeutics Inc, H2 2019
Pipeline by Bayer AG, H2 2019
Pipeline by Deciphera Pharmaceuticals Inc, H2 2019
Pipeline by Eddingpharm Inc, H2 2019
Pipeline by Eli Lilly and Co, H2 2019
Pipeline by Exelixis Inc, H2 2019
Pipeline by Pfizer Inc, H2 2019
Pipeline by PharmAbcine Inc, H2 2019
Pipeline by Q BioMed Inc, H2 2019
Pipeline by Samjin Pharm Co Ltd, H2 2019
Pipeline by Teva Pharmaceutical Industries Ltd, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Dormant Products, H2 2019 (Contd..2), H2 2019
Discontinued Products, H2 2019
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
COMPANIES MENTIONED
AsclepiX Therapeutics Inc
Bayer AG
Deciphera Pharmaceuticals Inc
Eddingpharm Inc
Eli Lilly and Co
Exelixis Inc
Pfizer Inc
PharmAbcine Inc
Q BioMed Inc
Samjin Pharm Co Ltd
Teva Pharmaceutical Industries Ltd
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
COMPANIES MENTIONED
AsclepiX Therapeutics Inc
Bayer AG
Deciphera Pharmaceuticals Inc
Eddingpharm Inc
Eli Lilly and Co
Exelixis Inc
Pfizer Inc
PharmAbcine Inc
Q BioMed Inc
Samjin Pharm Co Ltd
Teva Pharmaceutical Industries Ltd
